mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
|Articles|June 17, 2020
Cobra Biologics to Manufacture AstraZeneca’s COVID-19 Vaccine Candidate
Author(s)BioPharm International Editors
Cobra Biologics has signed a supply agreement to provide GMP manufacturing for AstraZeneca’s AZD1222 COVID-19 vaccine candidate.
Advertisement
Cobra Biologics, part of the Cognate BioServices family, has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19, Cobra announced in a June 16, 2020 press release. The production agreement is part of AstraZeneca’s program with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit, during the COVID-19 pandemic.
Cobra, along with other consortium members, will be manufacturing the vaccine, with first deliveries to begin in the United Kingdom in September 2020. Cobra is part of a consortium with the Jenner Institute, University of Oxford, and others, to rapidly develop, scale-up, and produce the recombinant adenovirus vector. Cobra says that it is bringing three additional viral vector suites online as part of its ongoing expansion program for advanced therapies.
Source:
Advertisement
Related to this article
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Advertisement
Advertisement